PMV Pharmaceuticals, Inc. - Common Stock, $0.00001 par value per share (PMVP)

CUSIP: 69353Y103

Q2 2023 13F Holders as of 30 Jun 2023

Holder snapshot 7 signals
Share change
+246,162
Put/Call ratio
17%
SEC-reported price per share
$6.26
Number of holders
104
Value change
+$3,281,155
Number of buys
58
Open additional details 1 more signal available
Number of sells
53
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
76,540,071

Security key

69353Y103

Report period

Q2 2023

Institutions

104

Top holders

10

Ownership snapshot

Top reported holders of PMVP - PMV Pharmaceuticals, Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Euclidean Capital LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
0/15
Latest evidence
31 Mar 2023
13F 3/4/5 Highest disclosed value: $31,305,877 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC has the largest disclosed position value at $31.31M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.
Disclosed position value Top 5
Euclidean Capital LLC $11.15M
INTERWEST PARTNERS X LP $10.04M
ORBIMED ADVISORS LLC $31.31M
BlackRock Finance, Inc. $19.22M
JPMORGAN CHASE & CO $19.09M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Euclidean Capital LLC
13F 3/4/5
Company · 10%+ Owner
—
denominator unverified
$11,147,056
2,336,909 shares
— 31 Mar 2023
INTERWEST PARTNERS X LP
3/4/5
10%+ Owner
—
denominator unverified
$10,040,531
4,502,480 shares
— 13 Jul 2021
Peter A. Thompson
3/4/5
Director, 10%+ Owner
—
denominator unverified
—
16,333 shares
— 02 Jun 2021
ORBIMED ADVISORS LLC
13F
Company
13F
—
denominator unverified
$31,305,877
6,563,077 shares
— 31 Mar 2023
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$19,223,905
4,030,169 shares
— 31 Mar 2023
JPMORGAN CHASE & CO
13F
Company
13F
—
denominator unverified
$19,094,000
4,002,874 shares
— 31 Mar 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
104
Shares
51,696,984
Rows available
104
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2023 vs Q3 2025 Across Filers

Q3 2025 holders
63
Q2 2023 holders
104
Holder diff
41
Investor Q3 2025 Shares Q2 2023 Shares Share Diff Share Chg % Q3 2025 value Q2 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .